About
Amid the dynamic biotechnology ecosystem, Patrick Mahaffy emerges as an unwavering anchor, steadfast in his endeavors in oncology-focused drug evolution across the US and Europe. Having once anchored the biotech shores of Boulder, Colorado, he now casts his expertise across the vibrant waters of South Florida.
Biotech Harbors
One of his signature ports, Clovis Oncology, inaugurated in 2009, symbolizes his maritime prowess. As the chief navigator, he directed Clovis towards uncharted territories of ovarian and prostate cancer solutions. In tandem, the organization dipped its oars into the novel waters of targeted radionuclide therapy. However, the turbulent waves of 2022, stirred by COVID-19's interference in cancer screenings and the FDA's hesitance regarding specific ovarian cancer treatments, posed navigational challenges.
Sailing further back in time, before commanding the ship of Clovis, he captained Pharmion from 2000, steering it until its merger with Celgene in 2008-a behemoth that later anchored alongside Bristol Myers Squibb. Earlier still, from 1992 to 1998, he helmed Nexstar Pharmaceuticals until it merged its voyage with Gilead Sciences. Under his seasoned captaincy, both ships charted innovative oncology routes in European and US waters.
Showcasing his maritime mastery, treatments birthed under his guidance stand as lighthouses or significant buoys in their respective medical waters.
Setting sail on his professional voyage, he navigated financial routes at Warburg Pincus from 1986 to 1992, surfacing as an astute investment navigator.
Academic Navigation
In academic waters, he etched his Master's in International Affairs on the illustrious map of Columbia University in 1986. This educational voyage followed closely after he secured his Bachelor's credentials in the same discipline from Lewis and Clark College in 1985.
Philanthropic Seas
While his charitable voyages often sail under the radar, they grace numerous philanthropic waters, particularly those supporting familial shores. He also consistently marks his presence on the Board of Trustees at Lewis & Clark College.
Charting Success
His visionary compass, cooperative maritime spirit, thirst for exploration, and rich experience in drug evolution have been the compass that rose to guide the firms he helmed. Lauded for mapping thriving commercial routes in the US and Europe, he ensures that therapeutic introductions under his command are maritime landmarks.
Beyond Nautical Duties
Away from his professional nautical charts, Patrick Mahaffy delves into diverse waters: scaling mountain terrains, mastering golf waves, and diving deep into literary oceans. An archaeological treasure discovered in 2009 at his Colorado base-relics from the ancient Clovis era-marked an unexpected maritime point of interest. Named the "he Cache," these artifacts provide rare insights into the Clovis era in North America and are now showcased at the University of Colorado History Museum. While his professional waters are vast and expansive, he treasures the tranquil bays he shares with his family and circle.
He is a notable figure in the biopharmaceutical sector, known for his substantial experience developing and commercializing oncology-targeted drugs in the United States and Europe. Throughout his illustrious career, he has held various leadership roles, including President, CEO, and Board Chair at multiple industry-leading firms. In addition, he has contributed as a board member to several rapidly growing biotech companies and is known for his dedication to mentoring emerging CEOs.
He possesses a sharp strategic vision and provides insightful commercial development, marketing, and portfolio strategy guidance. He is notably recognized for his expertise in innovative oncology therapeutics, including targeted radiotherapeutics. Beyond his association with traditional oncology firms, he has also extended his board service to companies specializing in immunotherapies for cancer, infectious diseases, and musculoskeletal therapeutics.
Most recently, he served as the President and CEO of Clovis Oncology, a company he co-founded in 2009. Under his leadership, Clovis successfully developed, obtained regulatory approvals for, and marketed Rubraca, a drug intended to treat ovarian and prostate cancer in the US and Europe. Additionally, Clovis initiated early-stage clinical trials for targeted radionuclide therapy. Unfortunately, the company had to wind down its operations in early 2023 due to the detrimental impact of COVID-19 on cancer diagnoses and FDA concerns regarding the outcomes of Rubraca and the broader class of PARP inhibitors in the treatment of ovarian cancer. It is important to note that the wider opinion leader community or other regulatory bodies did not share these concerns. As a result, Rubraca and PARP inhibitors remain the standard of care for ovarian cancer treatment.
Before his tenure at Clovis, he was President and CEO of Pharmion Corporation from 2000 to 2008. Pharmion, a global firm focused on developing and commercializing drugs for hematological and solid tumor cancers, was acquired by Celgene (now Bristol Myers Squibb) for $2.9 billion in 2008. Pharma's primary medicine, Vidaza, remains the standard for treating myelodysplastic syndrome and acute myeloid leukemia. In addition, Pharmion successfully achieved European approval for thalidomide as a treatment for multiple myeloma, despite the drug's historical association with congenital disabilities when previously used for morning sickness in Europe.
His initial role as CEO was at Nexstar Pharmaceuticals, where he served from 1992 to 1998. Nexstar, committed to discovering, developing, manufacturing, and commercializing products for severe and life-threatening illnesses, including cancer, was acquired by Gilead Sciences in 1999 for $550 million. Nexstars flagship drug, Ambisome, continues to be the standard of care for certain life-threatening fungal infections.
Throughout his remarkable career, Mahaffy has consistently championed developing and commercializing innovative oncology drugs in the US and Europe. His leadership has been instrumental in the success of three Boulder, Colorado-based firms that achieved public listings on the Nasdaq exchange. The marketed drugs developed and commercialized under his leadership at each of these companies remain the standard of care (or belong to the class considered the standard) for the conditions they are approved to treat in the US and Europe."
Biotech Harbors
One of his signature ports, Clovis Oncology, inaugurated in 2009, symbolizes his maritime prowess. As the chief navigator, he directed Clovis towards uncharted territories of ovarian and prostate cancer solutions. In tandem, the organization dipped its oars into the novel waters of targeted radionuclide therapy. However, the turbulent waves of 2022, stirred by COVID-19's interference in cancer screenings and the FDA's hesitance regarding specific ovarian cancer treatments, posed navigational challenges.
Sailing further back in time, before commanding the ship of Clovis, he captained Pharmion from 2000, steering it until its merger with Celgene in 2008-a behemoth that later anchored alongside Bristol Myers Squibb. Earlier still, from 1992 to 1998, he helmed Nexstar Pharmaceuticals until it merged its voyage with Gilead Sciences. Under his seasoned captaincy, both ships charted innovative oncology routes in European and US waters.
Showcasing his maritime mastery, treatments birthed under his guidance stand as lighthouses or significant buoys in their respective medical waters.
Setting sail on his professional voyage, he navigated financial routes at Warburg Pincus from 1986 to 1992, surfacing as an astute investment navigator.
Academic Navigation
In academic waters, he etched his Master's in International Affairs on the illustrious map of Columbia University in 1986. This educational voyage followed closely after he secured his Bachelor's credentials in the same discipline from Lewis and Clark College in 1985.
Philanthropic Seas
While his charitable voyages often sail under the radar, they grace numerous philanthropic waters, particularly those supporting familial shores. He also consistently marks his presence on the Board of Trustees at Lewis & Clark College.
Charting Success
His visionary compass, cooperative maritime spirit, thirst for exploration, and rich experience in drug evolution have been the compass that rose to guide the firms he helmed. Lauded for mapping thriving commercial routes in the US and Europe, he ensures that therapeutic introductions under his command are maritime landmarks.
Beyond Nautical Duties
Away from his professional nautical charts, Patrick Mahaffy delves into diverse waters: scaling mountain terrains, mastering golf waves, and diving deep into literary oceans. An archaeological treasure discovered in 2009 at his Colorado base-relics from the ancient Clovis era-marked an unexpected maritime point of interest. Named the "he Cache," these artifacts provide rare insights into the Clovis era in North America and are now showcased at the University of Colorado History Museum. While his professional waters are vast and expansive, he treasures the tranquil bays he shares with his family and circle.
He is a notable figure in the biopharmaceutical sector, known for his substantial experience developing and commercializing oncology-targeted drugs in the United States and Europe. Throughout his illustrious career, he has held various leadership roles, including President, CEO, and Board Chair at multiple industry-leading firms. In addition, he has contributed as a board member to several rapidly growing biotech companies and is known for his dedication to mentoring emerging CEOs.
He possesses a sharp strategic vision and provides insightful commercial development, marketing, and portfolio strategy guidance. He is notably recognized for his expertise in innovative oncology therapeutics, including targeted radiotherapeutics. Beyond his association with traditional oncology firms, he has also extended his board service to companies specializing in immunotherapies for cancer, infectious diseases, and musculoskeletal therapeutics.
Most recently, he served as the President and CEO of Clovis Oncology, a company he co-founded in 2009. Under his leadership, Clovis successfully developed, obtained regulatory approvals for, and marketed Rubraca, a drug intended to treat ovarian and prostate cancer in the US and Europe. Additionally, Clovis initiated early-stage clinical trials for targeted radionuclide therapy. Unfortunately, the company had to wind down its operations in early 2023 due to the detrimental impact of COVID-19 on cancer diagnoses and FDA concerns regarding the outcomes of Rubraca and the broader class of PARP inhibitors in the treatment of ovarian cancer. It is important to note that the wider opinion leader community or other regulatory bodies did not share these concerns. As a result, Rubraca and PARP inhibitors remain the standard of care for ovarian cancer treatment.
Before his tenure at Clovis, he was President and CEO of Pharmion Corporation from 2000 to 2008. Pharmion, a global firm focused on developing and commercializing drugs for hematological and solid tumor cancers, was acquired by Celgene (now Bristol Myers Squibb) for $2.9 billion in 2008. Pharma's primary medicine, Vidaza, remains the standard for treating myelodysplastic syndrome and acute myeloid leukemia. In addition, Pharmion successfully achieved European approval for thalidomide as a treatment for multiple myeloma, despite the drug's historical association with congenital disabilities when previously used for morning sickness in Europe.
His initial role as CEO was at Nexstar Pharmaceuticals, where he served from 1992 to 1998. Nexstar, committed to discovering, developing, manufacturing, and commercializing products for severe and life-threatening illnesses, including cancer, was acquired by Gilead Sciences in 1999 for $550 million. Nexstars flagship drug, Ambisome, continues to be the standard of care for certain life-threatening fungal infections.
Throughout his remarkable career, Mahaffy has consistently championed developing and commercializing innovative oncology drugs in the US and Europe. His leadership has been instrumental in the success of three Boulder, Colorado-based firms that achieved public listings on the Nasdaq exchange. The marketed drugs developed and commercialized under his leadership at each of these companies remain the standard of care (or belong to the class considered the standard) for the conditions they are approved to treat in the US and Europe."